Potential success could be head-scratcher for Novo Nordisk chair

If Novo Nordisk succeeds with its growth ambition, the company would face increasing complexity within its business, says Chair Helge Lund.

Photo: Novo Nordisk / PR

The organization would become more difficult to operate should Novo Nordisk reach its ambition of continuing on its current growth track, which has catapulted the company all the way to the upper echelons as one of the world’s biggest pharmaceutical companies.

”A lot of people probably don’t think about it in everyday life, but Novo Nordisk has actually become one of the world’s biggest pharmaceutical firms. We’re continuing to grow, and if we succeed with our strategy, we will have even more therapeutic areas in a few years,” says Helge Lund, chair of the board at Novo Nordisk, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs